Please provide your email address to receive an email when new articles are posted on . Baseline BMI may impact treatment effect of tirzepatide in patients with HFpEF and obesity. Distribution of ...
Please provide your email address to receive an email when new articles are posted on . Semaglutide lowered risk for kidney outcomes consistently across BMI subgroups in the FLOW trial. Body weight ...
Nefecon, an oral targeted-release formulation of budesonide that targets drug release into the distal ileum, provided significant improvements in the loss of kidney function in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback